Re: ‘Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials’  by Spanos, K. & Giannoukas, A.D.
Eur J Vasc Endovasc Surg (2015) 49, 353e355CORRESPONDENCERe: ‘Kakkos et al. Efﬁcacy and Safety of the New Oral
Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and
Edoxaban in the Treatment and Secondary Prevention of
Venous Thromboembolism: A Systematic Review and
Meta-analysis of Phase III Trials’
The systematic review and meta-analysis by Kakkos et al.1
highlights the non-inferior outcomes and safety of new
oral anticoagulants (NOAs) used in venous thromboembo-
lism (VTE) compared with conventional treatment with
vitamin K antagonists (VKAs). However, there are few areas
that remain unsettled and further analysis of the existing
trials may be needed.
The results could possibly be different if cost-
effectiveness and quality of life were analyzed. Although
the authors mentioned the presence of cost-effectiveness
studies of NOAs used to treat VTE,2,3 such analysis has
not been provided in this meta-analysis to assess the coste
beneﬁt ratio. One could reasonably argue that this issue
could have an important impact, similar to that of the cost-
effectiveness of NOAs versus VKAs, on the treatment of
atrial ﬁbrillation.4
Quality of life assessments of oral anticoagulants have been
attracting interest since as early as in 1991.5 As such, a speciﬁc
instrument has been developed and validated.6 Therefore,
the inclusion of lifetime quality adjusted life years and cost of
NOAs compared with VKAs as additional outcomes should be
assessed in previous and future clinical trials.
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We would like to thank the authors of this letter for giving
us the opportunity to discuss further the value of the new
oral anticoagulants (NOAs) in the management of venous
thromboembolism (VTE), which was the subject of a meta-
analysis recently published in the European Journal of
Vascular and Endovascular Surgery.
Several areas remain unsettled, and further analysis of the
existing trials may provide additional information on the ef-
ﬁcacy and safety in predeﬁned subgroups of the trials,
although this process will limit the power of the analysis.
Assessment of cost-effectiveness requires speciﬁc method-
ology, and was not the purpose of the investigation. This is
usually a stand-alone study based on the results of the
original studies. However, it is agreed that cost-effectiveness
studies should be performed, particularly in the secondary
prevention of VTE, where an improved patient survival with
the NOAs compared with placebo was evident from this
meta-analysis. Likewise, the reduced bleeding rate with the
NOAs compared with warfarin in VTE treatment is expected
to tip the balance in favour of the former. Ideally, cost-
effectiveness studies also should be carried out for each
NOA separately, because of the different properties of these
agents. Secondary prevention studies comparing the NOAs
with warfarin head-to-head in patients with unprovoked VTE
are scarce (RE-SONATE trial), and could be performed to
